Phase 3 pulmonary arterial hypertension trial of ralinepag now fully enrolled, results are expected in 2026, Pulmonary Hypertension News, June 27, 2025

Ralinepag is a novel prostacyclin receptor agonist. It is designed to mimic prostacyclin, a molecule that reduces blood pressure by relaxing blood vessels. It is a once-daily oral formulation. United Therapeutics has announced the completion of enrollment for its ADVANCE OUTCOMES, a Phase 3 clinical trial testing ralinepag for pulmonary arterial hypertension (PAH). The study […]

Phase 3 pulmonary arterial hypertension trial of ralinepag now fully enrolled, results are expected in 2026, Pulmonary Hypertension News, June 27, 2025 Read Post »

Computer modeling used in study to simulate long-term mortality/morbidity in patients with pulmonary arterial hypertension If sotatercept Is delayed, Advances in Therapy, June 17, 2025

Researchers used computer modeling to compare immediate versus delayed (2-year) treatment with sotatercept, a new pulmonary arterial hypertension medication, to predict lifetime outcomes. Study Method: Building on the findings of the phase 3 STELLAR trial on sotatercept the authors of the study refer to a population health model which was recently published assessing the long-term

Computer modeling used in study to simulate long-term mortality/morbidity in patients with pulmonary arterial hypertension If sotatercept Is delayed, Advances in Therapy, June 17, 2025 Read Post »

Pulmonary arterial hypertension (PAH): sex-specific differences and outcomes, Therapeutic Advances in Respiratory Disease, Jan-Dec 2025

Pulmonary arterial hypertension has a higher prevalence in women than men, yet notable sex-based differences influence disease presentation, treatment response, and outcomes. Based on data from major pulmonary arterial hypertension clinical trials the authors of a recent study published in Therapeutic Advances in Respiratory Disease have found that: These sex-based differences, say the authors, highlight

Pulmonary arterial hypertension (PAH): sex-specific differences and outcomes, Therapeutic Advances in Respiratory Disease, Jan-Dec 2025 Read Post »

Anti-remodeling therapies in pulmonary arterial hypertension (PAH), Trends in Pharmaceutical Science, June 19, 2025

Existing treatments pulmonary arterial hypertension (PAH) widen blood vessels, can help relieve symptoms and extend life, but cannot cure the disease or repair the damaged vessels. The field is now moving toward treatments that could actually modify the underlying disease process, based on promising laboratory research that’s being tested in patients. Two important breakthroughs include

Anti-remodeling therapies in pulmonary arterial hypertension (PAH), Trends in Pharmaceutical Science, June 19, 2025 Read Post »

PVRI Drug Discovery Symposium, June 16-17: Key Insights, Louise Bouman, Chair of PHA Netherlands and Board Member of the Alliance for Pulmonary Hypertension

Louise Bouman, Chair of Stichting Pulmonale Hypertensie (PHA Netherlands) and Board Member of the Alliance for Pulmonary Hypertension is just back from Amsterdam where she attended the Pulmonary Vascular Institute (PVRI) Symposium on Drug Discovery and Development taking place on June 16-17. “I recently had the opportunity to attend an inspiring symposium organized by the

PVRI Drug Discovery Symposium, June 16-17: Key Insights, Louise Bouman, Chair of PHA Netherlands and Board Member of the Alliance for Pulmonary Hypertension Read Post »

Major Study Shows Sotatercept Helps High-Risk Pulmonary Arterial Hypertension Patients, New England Journal of Medicine, May 29, 2025

This study focused on some of the sickest pulmonary arterial hypertension patients – those with advanced disease who were already on the best available treatments but still faced a high risk of dying within the next year. For these patients, doctors have traditionally had limited options. Researchers enrolled 172 high-risk patients who were already receiving

Major Study Shows Sotatercept Helps High-Risk Pulmonary Arterial Hypertension Patients, New England Journal of Medicine, May 29, 2025 Read Post »

A new Phase 2b trial on treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary arterial hypertension (PAH) shows very promising results, INSMED

TPIP is a new version of an existing pulmonary arterial hypertension medication called treprostinil. It is designed as a “prodrug” – meaning it becomes active only after the body processes it. The key advantage is that TPIP can be taken as a dry powder in a capsule-based inhaler, once daily. In a 102-patient phase 2b

A new Phase 2b trial on treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary arterial hypertension (PAH) shows very promising results, INSMED Read Post »

Scientists Find Four Types of Pulmonary Hypertension Using Blood Protein Patterns, American Journal of Respiratory and Critical Care Medicine, May 9, 2025

Patients with pulmonary hypertension are classified according to clinical criteria to inform treatment decisions. Knowledge of the molecular drivers of pulmonary hypertension might better inform treatment choice, say researchers involved in a study published in May in the American Journal of Respiratory and Critical Care Medicine. The researchers studied blood samples from 470 people who

Scientists Find Four Types of Pulmonary Hypertension Using Blood Protein Patterns, American Journal of Respiratory and Critical Care Medicine, May 9, 2025 Read Post »

10-year Data on Oral Selexipag: Long-Term Survival, Safety, and Dosing Insights in Pulmonary Arterial Hypertension (PAH), oral session at ISHLT congress, April 29, 2025 

Selexipag is an oral selective IP prostacyclin receptor agonist. This study, presented during an oral session at the International Society for Heart and Lung Transplant (ISHLT) congress on April 29, 2025, provides the longest follow-up data available for any pulmonary arterial hypertension therapy, tracking 574 patients originally randomized to selexipag in the GRIPHON trial, with

10-year Data on Oral Selexipag: Long-Term Survival, Safety, and Dosing Insights in Pulmonary Arterial Hypertension (PAH), oral session at ISHLT congress, April 29, 2025  Read Post »

Comparative Analysis of Survival in Pulmonary Arterial Hypertension for Patients Treated with Selexipag in Clinical Practice (EXPOSURE Study), Drugs-Real World Outcomes, April 30, 2025

The EXPOSURE study compared survival rates between pulmonary arterial hypertension (PAH) patients newly treated with selexipag versus other pulmonary arterial hypertension-specific therapies. Survival analyses in EXPOSURE suggest a reduced risk of mortality among the cohort of patients newly initiated on selexipag compared with the modelled cohort newly initiated with other pulmonary arterial hypertension-specific therapies. Further

Comparative Analysis of Survival in Pulmonary Arterial Hypertension for Patients Treated with Selexipag in Clinical Practice (EXPOSURE Study), Drugs-Real World Outcomes, April 30, 2025 Read Post »

New study explores whether the withdrawal of prostacyclin therapies is possible after initiation of sotatercept, European Respiratory Journal 2025

Prostacyclin therapies, for pulmonary arterial hypertension, especially the parenteral ones, are associated with treatment burden, risks, and high costs. Authors Karen M Olsson, Jan Fuge, Da-Hee Park,Jan C. Kamp, and Marius M. Hoeper have investigated this possibility in a small series of pulmonary arterial hypertension patients treated with sotatercept. Withdrawal of selexipag was found safe,

New study explores whether the withdrawal of prostacyclin therapies is possible after initiation of sotatercept, European Respiratory Journal 2025 Read Post »

Societal Costs Associated With Pulmonary Arterial Hypertension Subgroups: A Study Utilizing Linked National Registries, Pulmonary Circulation, April 17, 2025

Pulmonary arterial hypertension (PAH) represents a significant economic burden on society, as revealed by a comprehensive Swedish study published on Pulmonary Circulation on April 17, 2025, examining the societal costs associated with this condition. The research tracked patients across various pulmonary arterial hypertension subgroups—idiopathic/hereditary pulmonary arterial hypertension, pulmonary arterial hypertension associated with connective tissue disease,

Societal Costs Associated With Pulmonary Arterial Hypertension Subgroups: A Study Utilizing Linked National Registries, Pulmonary Circulation, April 17, 2025 Read Post »

Pulmonary Artery Denervation (PADN) shows promise as a novel therapeutic approach in pulmonary hypertension, International Journal of Cardiology, May 2025 edition

Pulmonary Artery Denervation (PADN) shows promise as a novel therapeutic approach targeting the sympathetic nervous system’s role in pulmonary hypertension, reveal the findings of a metanalysis reviewing 14 studies, involving 372 patients. Pulmonary Artery Denervation improved several key hemodynamic parameters and clinical outcomes. The meta-analysis was published in the May 2025 edition of the International Journal

Pulmonary Artery Denervation (PADN) shows promise as a novel therapeutic approach in pulmonary hypertension, International Journal of Cardiology, May 2025 edition Read Post »

Medication adherence and clinical outcomes in patients with pulmonary arterial hypertension or distal chronic thromboembolic pulmonary hypertension, British Medical Journal Open Respiratory Research, April 5, 2025

The findings of a prospective study on 93 patients (66% women, 75% PAH, 25% CTEPH, 57±17 years), all on pulmonary hypertension-targeted oral medication, between 2013 and 2023, were recently published in the British Medical Journal Open Respiratory Research. These reveal that mean MPR (Medication Possession Ratio) and self-reported adherence were overall high, with 78% of patients

Medication adherence and clinical outcomes in patients with pulmonary arterial hypertension or distal chronic thromboembolic pulmonary hypertension, British Medical Journal Open Respiratory Research, April 5, 2025 Read Post »

Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death, New England Journal of Medicine, March 31, 2025

An article published in the New England Journal of Medicine on March 31 titled “Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death” reports on the findings of ZENITH, a phase 3 trial which evaluated sotatercept as an add-on therapy for high-risk pulmonary arterial hypertension patients (functional class II-IV) already on maximum

Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death, New England Journal of Medicine, March 31, 2025 Read Post »

Breaking news! Important update on the ZENITH trial on Winrevair (sotatercept) in pulmonary arterial hypertension from the American College of Cardiologists Scientific Annual Scientific Session, March 31, 2025

A very important update on the phase 3 ZENITH trial for Winrevair (sotatercept) in pulmonary arterial hypertension was presented today at the American College of Cardiologists Annual Scientific Session in Boston, USA. The ZENITH trial evaluated Winrevair compared to placebo in adults with PAH, WHO Group 1, functional class III or IV, at high risk

Breaking news! Important update on the ZENITH trial on Winrevair (sotatercept) in pulmonary arterial hypertension from the American College of Cardiologists Scientific Annual Scientific Session, March 31, 2025 Read Post »

Positioning Imatinib for Pulmonary Arterial Hypertension: A Dose Finding Phase 2 Study, American Journal for Respiratory Critical Care Medicine, March 2025

Imatinib for pulmonary arterial hypertension was the first antiproliferative approach in this condition’s treatment and may still be relevant today despite its complicated history. Originally developed as a cancer therapy (tyrosine kinase inhibitor), it showed very good results in pulmonary arterial hypertension, creating a lot of expectation when the IMPRES study was presented at the

Positioning Imatinib for Pulmonary Arterial Hypertension: A Dose Finding Phase 2 Study, American Journal for Respiratory Critical Care Medicine, March 2025 Read Post »

Historical milestones and future horizons: exploring the diagnosis and treatment evolution of the pulmonary arterial hypertension in adults, Expert opinion on pharmacotherapy, March 19, 2025

This review, published on Expert Opinion on Pharmacotherapy on March 19, 2025, chronicles the evolution of pulmonary arterial hypertension (PAH) treatment from historical milestones to current challenges. Beginning with Ernst von Romberg’s first clinical description in 1891 and the advent of cardiac catheterization, pulmonary arterial hypertension diagnosis and treatment have advanced significantly in past decades.

Historical milestones and future horizons: exploring the diagnosis and treatment evolution of the pulmonary arterial hypertension in adults, Expert opinion on pharmacotherapy, March 19, 2025 Read Post »

Mono and combination therapies in pulmonary arterial hypertension patients with comorbidities: A COMPERA analysis, ESC Heart Failure, March 4, 2025

A recent study published in ESC Heart Failure (March 4, 2025) compared initial monotherapy versus combination therapy in pulmonary arterial hypertension (PAH) patients with cardiovascular comorbidities. Results showed that the combination therapy group experienced greater improvements in functional class, BNP/NT-proBNP levels, and overall risk status compared to monotherapy patients. However, no significant differences were observed

Mono and combination therapies in pulmonary arterial hypertension patients with comorbidities: A COMPERA analysis, ESC Heart Failure, March 4, 2025 Read Post »

“Pulmonary arterial hypertension in Latin America. The age and comorbidity paradox”, International Journal of Cardiology Congenital Heart Disease (Volume 9, March 2025)

A recent analysis published in the International Journal of Cardiology Congenital Heart Disease (Volume 9, March 2025) examines the evolving landscape of pulmonary arterial hypertension (PAH). While traditionally viewed as primarily affecting young adult women without other health conditions, newer registry data from developed countries reveals a shift toward older patients with multiple co-morbidities like

“Pulmonary arterial hypertension in Latin America. The age and comorbidity paradox”, International Journal of Cardiology Congenital Heart Disease (Volume 9, March 2025) Read Post »

TRANSLATE »
Scroll to Top